Clinical trial · Observational
Abraxane in Treatment of Metastatic Breast Cancer
Assessment of Abraxane in Metastatic Breast Cancer in a Real-life Setting
NCT02555696CI-TRIAL-00026109completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This observational project is collecting tolerability, safety and efficacy data with the routine use of Abraxane in the treatment of metastatic breast cancer. Additionally data on the dosage of Abraxane and general data on the disease and the health status of the patient will be collected.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Metastatic Breast Cancer | Malignant Breast Neoplasm | CURATED_BROADER | 0.78 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| nab-paclitaxel | Drug | Nab-paclitaxel | ALIAS |
Design
Arms and outcomes
Arms (1)
- label
- nab-paclitaxel
- description
- nab-paclitaxel 260mg/m\^2 in intravenous (IV) infusion every 3 weeks until progression or toxicity
- interventionNames
- Drug: nab-paclitaxel
Primary outcomes (1)
- measure
- Adverse Events
- timeFrame
- Up to 3 years
- description
- Includes the number of participants with adverse events
Secondary outcomes (1)
- measure
- Overall Response
- timeFrame
- Up to 3 years
- description
- Number of participants who achieve a response
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Patients with metastatic breast cancer (according to European Summary of Product characteristics (SmPC) 2. Signed Informed Consent 3. Participants \> 18 Years of Age Exclusion Criteria: 1. Pregnant or lactating females 2. Neutrophils \<1.5 X 10\^9/L 3. Hypersensivity to nab-paclitaxel
References
Publications (0)
Data not yet available
No reference posted for this study.